Natera seeks Japan PMDA approval for Signatera test in muscle-invasive bladder cancer
NTRA•Japan filing for Signatera in bladder cancer
Natera filed Signatera with Japan’s PMDA for approval as a companion diagnostic in muscle-invasive bladder cancer.
The submission follows PMDA approval for Signatera in colorectal cancer in June.
Natera cited IMvigor011 Phase 3 trial data supporting the muscle-invasive bladder cancer filing.
